Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PCDH10 divergent transcript (PCDH10-DT) is a presumptive non-coding RNA transcript transcribed divergently from the *PCDH10* gene locus. Divergent transcripts are a class of long non-coding RNAs that originate on the opposite DNA strand of a protein-coding gene, often sharing a bidirectional promoter. There is evidence that other divergent lncRNAs in the nervous system can regulate the expression of their neighboring protein-coding gene, but there is currently no direct experimental or functional information on PCDH10-DT specifically. There is currently no direct evidence or established biological function for the PCDH10 divergent transcript. Some other divergent lncRNAs regulate their neighboring genes in cis or trans, including roles in *cis*-regulation of protein-coding gene expression. There is no direct evidence linking PCDH10-DT to disease. *PCDH10* itself is a tumor suppressor in various cancers, but disease implication for the divergent transcript is not established in current literature. The main protein-coding gene, *PCDH10*, is a protocadherin with established tumor suppressor roles in multiple cancers, but the divergent transcript itself is not a recognized receptor, enzyme, channel, or other common druggable target and does not appear to have a defined molecular or clinical function at present. PCDH10-DT is most likely a long non-coding RNA, not a receptor or traditional drug target. No known active drugs, mechanisms of action, biomarkers, or safety considerations are associated with PCDH10-DT. Function, disease role, and canonical naming remain unclear and are not standardized in major gene or transcript resources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PCDH10 divergent transcript (PCDH10-DT).